Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission
Provided By GlobeNewswire
Last update: Nov 13, 2025
RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA, non-invasive blood sensor, toward regulatory submission and future commercialization.
Read more at globenewswire.com
